Neovascular age-related macular degeneration (nAMD) is a leading cause of visual impairment in the elderly population.[@bib1] Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment can delay the degenerative process, the occurrence of sub-macular hemorrhages (SMH) can complicate the clinical picture, leading to sudden and irreversible vision loss.[@bib2]

Coronavirus Disease 2019 (COVID-19) has rapidly spread as a pandemic, with Northern Italy being one of the most affected regions across the world.[@bib3]

The implementation of national lockdown (starting March 8, 2020) and social containment measures have undoubtedly generated anxiety in the local population, resulting in significant nonattendance to scheduled office visits.[@bib4] After the initial efforts to cope with this unexpected public health emergency, our clinicians are starting to weigh in on the impact of this pandemic on clinical practice.

Aim of this study is to report the attendance rates to the service of Medical Retina and the incidence of large SMH in an Italian tertiary center for nAMD during the early months of COVID-19 pandemic.

The admissions, clinical records and imaging studies of nAMD patients accessing to the Eye Clinic of Luigi Sacco Hospital (Milan, Italy) from March 1 to April 30, 2020 were retrospectively reviewed. Ethics approval was obtained from the local institutional review board and the procedures adhered to the tenets of the Declaration of Helsinki.

The occurrence of SMH secondary to choroidal neovascular membrane was collected from clinical records and confirmed by means of multimodal imaging, including color fundus photography, optical coherence tomography and fundus autofluorescence. Only nAMD patients already undergoing pro-re-nata anti-VEGF treatment with SMH of at least one disc-diameter within the macular region were included.[@bib2] Patients with previous history of large SMH were excluded from the study. Patients affected by bilateral nAMD are routinely treated with an interval of at least 14 days due to Italian Health Authorities' regulations.

The attendance rate to the clinic and the incidence rate of SMHs from the same months of the previous year (March-April 2019) were analyzed as controls. Since the majority of our patients were switched to bevacizumab from September 2019 for economic reasons, an additional control bimester (October 1 to November 30, 2019) was considered to avoid biases related to drug selection.

The attendance rates were calculated in relation to the scheduled office visits and intravitreal treatments. Student's T test was used to explore the differences among the weekly attendances in distinct time periods. The incidence rate of SMH was instead obtained measuring the number of SMH cases occurring per-month among scheduled nAMD patients. Poisson regression analysis was used to assess the ratio between the incidence rates (IRR) of large SMH among the different study periods. All the analyses were performed with IBM SPSS Statistics for Macintosh, version 26.0 (IBM corporation; Armonk, NY). Statistical significance was set at p\<0.05.

Overall, 6568 consecutive nAMD patients attended our clinic for office visits in the three analyzed periods (mean age, 76.2±6.3 years; 2071 males, 43.9%).

During the 8 weeks following national lockdown, a mean of 95±30 patients attended office visits every week (attendance rate: 37%; range: 23-51%). This resulted in a 68% and 71% decrease of office visits compared with the two control periods (297±91 and 324±37 per week, respectively; both p\<0.001).

The attendance rate for intravitreal anti-VEGF treatments was of 58% (range: 48-68%). A significant drop (39%) was observed when compared with control periods (122±29 vs. 200±40 injections per week; p\<0.001).

A total of 41 patients presented with large SMH during the three analyzed periods (mean age, 82.2±5.4 years; 16 males, 39%). With respect to the prior examination, visual acuity significantly dropped from 0.57±0.16 LogMAR (approximately 20/70 Snellen equivalents, range: 0.15-1.0 LogMAR) to 1.66 LogMAR (approximately 20/900, range: 1.20-2.30 LogMAR; p\<0.001). The occurrence of SMH peaked in April 2020, with an incidence rate of 1 SMH case per 79 scheduled patients-month (1.3%). This rate was significantly higher than the rates collected from all the other studied months (IRR range: 3.21-4.92; p-value range: 0.005-0.015) (Figure 1 available at <http://www.aaojournal.org>).

While only two SMH cases (8.7%) had missed the scheduled appointments during control periods, six patients (40%) presenting with large sub-macular hemorrhage in April 2020 did not attend office visits or anti-VEGF treatments in the previous month (p=0.035). In April 2020, the interval between the appearance of large SMH and the last intravitreal anti-VEGF injection was significantly longer than the usual interval between two intravitreal anti-VEGF injections for this subset of patients (3.6±0.8 vs. 1.9±0.5 months; p=0.01).

Complete demographic data and rates are reported in [Table 1](#tbl1){ref-type="table"} . Figure 2 shows the weekly attendance to scheduled appointments and SMH incidence during the three analyzed periods (available at <http://www.aaojournal.org>).Table 1Comparison of weekly visits, weekly intravitreal treatments, and submacular hemorrhages between two months during the Covid-19 outbreak and four control months.Age *(mean ± SD)*Study PeriodControl PeriodsApril 2020March 2020November 2019October 2019April 2019March 2019**Weekly Visits**76,2 ± 6,3Scheduled, *n (mean ± SD)*263,8 ± 29,4259,3 ± 26,0338,7 ± 30,9375,3 ± 13,3289,1 ± 54,2357,1 ± 19,3Attended, *n (mean ± SD)*109,5 ± 28,1398,3 ± 64,0324,8 ± 27,5356,5 ± 16,9268,3 ± 64,9327,1 ± 27,7Attendance Rate*, %*41,5%37,9%95,9%95,0%92,8%91,6%**Weekly Intravitreal Treatments**78,4 ± 7,2Scheduled, *n (mean ± SD)*216,1 ± 41,8197,1 ± 11,1239,3 ± 13,4231,2 ± 6,9213,0 ± 35,3222,0 ± 8,0Attended, *n (mean ± SD)*134,4 ± 31,0108,4 ± 16,5224,5 ± 9,5219,4 ± 6,8194,5 ± 28,7206 ± 9,1Attendance Rate, *%*62,2%55,0%93,8%94,9%91,3%92,8%**Submacular Hemorrhages**82,2 ± 5,4Number per month, *n*1536656Incidence rate, *(per scheduled visits)*1 per 79,11 per 389,01 per 254,01 per 281,51 per 260,21 per 267,8[^2]

This report reveals that a meaningful decrease in the attendance rate to our clinic was followed by an ominous increment of large sub-macular hemorrhages during the early months of Covid-19 pandemic.

Several real-world studies have reported that poor adherence to treatment or to strict follow-up can be responsible for worse visual outcomes in nAMD.[@bib5] ^,^ [@bib6]

We hypothesize that nonattendance to scheduled appointments after the implementation of national lockdown might have partially contributed to the significant increase in the occurrence of large SMH. While this might be a plausible explanation, we acknowledge that a selection bias may exist as patients with SMH are more prone to refer to our attention due to the sudden worsening of central vision. However, the higher number of total hemorrhages in April 2020 and the elevated rate of nonattendance to office visits among SMH cases seem to support our hypothesis.

In conclusion, our findings confirm that Covid-19 pandemic is leaving the medical community with indirect consequences to address. This seems particularly true for nAMD, where regular follow-up visits and intravitreal treatments are essential to maintain good vision and prevent serious complications. It is likely that ophthalmologists in the next future will need to manage a higher number of complications, reorganize their clinical practice in observance of social containment measures, and possibly implement telemedicine programs introducing home-monitoring equipment.[@bib7]
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